Inovio Pharmaceuticals Inc

NASDAQ:INO   3:59:59 PM EDT
12.60
+0.08 (+0.64%)
4:32:32 PM EDT: $12.62 +0.02 (+0.16%)
Products, Regulatory

Inovio Announces Initiation Of Phase 2 Segment Of Phase 2/3 Clinical Trial For COVID-19 DNA Vaccine Candidate

Published: 11/16/2020 12:30 GMT
Inovio Pharmaceuticals Inc (INO) - Inovio Announces Initiation of Phase 2 Segment of Its Phase 2/3 Clinical Trial for Its Covid-19 Dna Vaccine Candidate, Ino-4800; Trial Will Be Funded by the U.S. Department of Defense.
Inovio Pharmaceuticals - Received Clearance From FDA to Proceed With Phase 2 Segment of Its Planned Phase 2/3 Clinical Trial for Ino-4800.